Two patients with catatonic depression in bipolar disorder who were not medically fit for electroconvulsive therapy (ECT) received intravenous ketamine instead. Both patients' symptoms resolved and they returned to their baseline level of functioning. During the COVID-19 pandemic, when ECT poses risks as an aerosol-generating procedure and resources are limited, ketamine therapy for catatonia may be a beneficial alternative or supportive treatment to ECT, warranting further research.
A randomized controlled trial will test whether a mindfulness mobile app can improve mental health in pregnant women. The study will enroll 360 prenatal women from Mater Mothers' Hospital, assigning them to either use the app or receive usual care. Over 11 months, researchers will measure changes in postnatal depression, mother-infant bonding, and quality of life. A cost-effectiveness analysis will also be performed. Some participants will provide feedback in focus groups. Previous research suggests mindfulness can reduce stress, anxiety, depression, and sleep problems during pregnancy. The intervention carries low risk and may benefit women who cannot attend in-person appointments due to distance, cost, time, or health issues.